title: Genetic variants of TNFSF4 and risk for carotid artery disease and stroke.
abstract: In two independent human cohorts, the minor allele of SNP rs3850641 in TNFSF4 was significantly more frequent in individuals with myocardial infarction than in controls. In mice, Tnfsf4 expression is associated with increased atherosclerosis. The expression of TNFSF4 in human atherosclerosis and the association between genotype and cerebrovascular disease have not yet been investigated. TNFSF4 messenger RNA (mRNA) levels were significantly higher in human atherosclerotic lesions compared with controls (730 +/- 30 vs 330 +/- 65 arbitrary units, p < 0.01). TNFSF4 was mainly expressed by macrophages in atherosclerotic lesions. In cell culture, endothelial cells upregulated TNFSF4 in response to tumor necrosis factor alpha (TNF-alpha; 460 +/- 110 vs 133 +/- 8 arbitrary units, p < 0.001 after 6 h of stimulation). We analyzed the TNFSF4 gene in 239 patients who had undergone carotid endarterectomy and 138 matching controls from The Biobank of Karolinska Carotid Endarterectomies and Stockholm Heart Epidemiology Program cohorts and 929 patients and 1,382 matching controls from the Sahlgrenska Academy Study on Ischemic Stroke and Case Control Study of Stroke cohorts, limiting inclusion to patients with ischemic stroke. Participants were genotyped for the rs3850641 SNP in TNFSF4. Genotype associations were neither found with TNFSF4 mRNA levels nor with atherosclerosis associated systemic factors or risk for stroke. This study shows that TNFSF4 is expressed on antigen-presenting cells in human carotid atherosclerotic lesions but provides no evidence for an association of TNFSF4 gene variation with the risk for ischemic stroke.
authors.affiliation: Center for Molecular Medicine, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. Peder.Olofsson@ki.se
authors.forename: P S
authors.initials: PS
authors.lastname: Olofsson
authors.forename: L A
authors.initials: LA
authors.lastname: Söderström
authors.forename: C
authors.initials: C
authors.lastname: Jern
authors.forename: A
authors.initials: A
authors.lastname: Sirsjö
authors.forename: M
authors.initials: M
authors.lastname: Ria
authors.forename: E
authors.initials: E
authors.lastname: Sundler
authors.forename: U
authors.initials: U
authors.lastname: de Faire
authors.forename: P G
authors.initials: PG
authors.lastname: Wiklund
authors.forename: J
authors.initials: J
authors.lastname: Ohrvik
authors.forename: U
authors.initials: U
authors.lastname: Hedin
authors.forename: G
authors.initials: G
authors.lastname: Paulsson-Berne
authors.forename: A
authors.initials: A
authors.lastname: Hamsten
authors.forename: P
authors.initials: P
authors.lastname: Eriksson
authors.forename: G K
authors.initials: GK
authors.lastname: Hansson
mesh_terms: D000368:Aged; D050197:Atherosclerosis / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D002340:Carotid Artery Diseases / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D015331:Cohort Studies; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005455:Fluorescent Antibody Technique; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D053278:OX40 Ligand / Q000235:genetics* / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D020521:Stroke / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D053278:OX40 Ligand; D012333:RNA, Messenger; C089251:TNFSF4 protein, human; D014409:Tumor Necrosis Factor-alpha